Rank #1902EDIT

Editas Medicine, Inc.

$1.81

5.23% (Daily)

Market Cap

$176.69M

Revenue

$46.38M

Rank by MCap

#1902

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Gilmore O'Neill M.D.

Headquarters

Cambridge, MA

Employees

246

About Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in...